Sartorius Stedim Biotech: Annual Report of the Liquidity Contract with the Stockbroker Company Gilbert Dupont

Regulatory News:

Under the liquidity contract concluded between Sartorius Stedim Biotech S.A. and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account at December 31, 2015:

• Number of shares: 658
• Liquidity account cash balance: € 228,739.83

For information, the following assets appeared on the annual report of the liquidity contract of June 30, 2015:

• Number of shares: 464
• Liquidity account cash balance: € 109,772.60

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,600 people, and in 2014 earned sales revenue of 683,5 million euros.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160119006237/en/

Sartorius Stedim BiotechAndreas TheisenDirector Investor Relations+49(0)[e-mail]